CLINICAL TRIALS AND OBSERVATIONS Hepatic toxicity and prognosis in hepatitis C virus–infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis
نویسندگان
چکیده
1Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama; 2Department of Hematology, Saitama Medical University International Medical Center, Hidaka; 3Department of Hematology and Oncology, Tokai University, Isehara; 4Division of Hematology, Kanto Medical Center NTT EC, Tokyo; 5Division of Hematology, Niigata University Graduate School of Medical & Dental Sciences, Niigata; 6Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya; 7Department of Hematology and Oncology, Fujita-Health University School of Medicine, Toyoake; 8Medical Oncology/Hematology, Cancer Institute Hospital, Tokyo; 9Department of Oncology Hematology, Fukuoka University Hospital, Fukuoka; 10Internal Medicine, National Okayama Medical Center, Okayama; 11Department of Hematology, Chugoku Chuo Hospital, Fukuyama; 12Department of Hematology, Gunma Prefectural Cancer Canter, Ota; 13Department of Hematology, Hiroshima University, Hiroshima; 14Department of Hematology, Nishigunma National Hospital, Shibukawa; 15Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama; 16Division of Epidemiology and Prevention, Aichi Cancer Center Institute, Nagoya; and 17Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
Approximately 60% of patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) are curable with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemoimmunotherapy. Epratuzumab (E) is an unlabeled anti-CD22 monoclonal antibody with efficacy in relapsed DLBCL. This phase 2 trial tested the safety and efficacy of combining E with R-CHOP (ER-CHOP) in untreated...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era Zheng Zhou, Laurie H. Sehn, Alfred W. Rademaker, Leo I. Gordon, Ann S. LaCasce, Allison Crosby-Thompson, Ann Vanderplas, Andrew D. Zelenetz, Gregory A. Abel, Maria A. Rodriguez, Auayporn Nademanee, Mark S. Kaminski, Myron S. Czuczman, Michael Millenson, Joyce Niland...
متن کاملCLINICAL TRIALS AND OBSERVATIONS The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity, with patients exhibiting a wide range of outcomes. The addition of rituximab to CHOP chemotherapy (R-CHOP)has led to a marked improvement in survival and has called into question the significance of previously recognized prognostic markers. Since randomized controlled trials of R-CHOP in DLBCL have included select subgroups of pat...
متن کاملCLINICAL TRIALS AND OBSERVATIONS The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/ bortezomib/rituximab combination. Patients with relapsed or refractory indolent and mantle cell lymphoma with adequ...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
Second-line chemotherapy followed by high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) cures less than half of the patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Prognostic models capable of predicting outcome are essential. In 3 sequential clinical trials, conducted from January 1993 to August 2000, we treated 150 patients with relapsed or pr...
متن کامل